Dr. Yibin Wang is currently a Professor of Molecular Medicine in the David Geffen School of Medicine at UCLA. He is the Vice Chair for Molecular, Cellular and Integrated Physiology Interdepartmental Ph.D. Program.  Dr. Wang received his Ph.D. in molecular genetics and cell biology from Baylor College of Medicine and post-doctoral training in neurobiology and molecular cardiology at The Scripps Research Institute and University of California at San Diego. Dr. Wang’s research mainly focuses on genetic and molecular mechanisms of heart failure and metabolic disorders. His lab has made major advances in uncovering stress-signaling mechanisms in the pathogenesis of heart failure, and revealed functional importance amino acids catabolism in heart failure and metabolic disorders. In addition, his lab reported novel regulatory mechanisms in cardiac transcriptome reprogramming involving RNA splicing regulation and non-coding RNA mediated epigenetic modulation. He has published over 220 peer-reviewed manuscripts in high quality scientific journals, including Nature Medicine, Journal of Clinical Investigation, Circulation, Circulation Research, and PNAS. Dr. Wang received an Established Investigator Award from American Heart Association in 2005. He was awarded the title of Chang-Jiang Scholar from Minister of Education of China in 2009. He currently serves in the editorial board of Journal of Biological Chemistry, Circulation Research, and Associate Editor for Journal of Molecular and Cellular Cardiology. Dr. Wang is a member of the leadership committees for AHA and ISHR North American Section. He has served in more than 30 Ph.D. thesis committees, and is currently the course master and Associate Director of the Molecular, Cellular and Integrated Physiology Ph.D. program at UCLA.  Dr. Wang has 4 patents filed and 3 licensed, and he is the scientific co-founder of Ramino Biotherapeutics Inc, a start-up company focusing on novel therapies for cardiometabolic diseases.